Reclast news from FierceBiotech
NewsALSO NOTED: FDA to speed up generic approval; Genfit starts Phase II trials; and much more...
Could the steady trickle of generics approvals out of the FDA suddenly become a rapid stream? The agency is touting an initiative, called Generic Initiative for Value and Efficiency (GIVE), to speed Read more...
ALSO NOTED: Knopf tapped to run Acceleron; FDA clears Samaritan IND; Wockhardt in hunt for Par; and much more...
> Chutes & Ladders: Acceleron Pharma has named John L. Knopf, Ph.D., as its new CEO. Dr. Knopf, a founder of Acceleron, has served as the executive vice president of corporate Read more...
| Press ReleasesPRESS RELEASE: First Osteoporosis Study in Patients with Hip Fracture Finds Aclasta-reclast Prevents Fractures First Osteoporosis Study in Patients with Hip Fracture Finds Once-yearly Aclasta-reclast Prevents Additional Fractures and Improves Survival Study of more than 2,100 patients who suffered a hip Read more... |
Get more Reclast coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends